Find It Early Act
- Sponsor
- Rep. DeLauro, Rosa L. [D-CT-3]
- Committees
- Veterans' Affairs Committee (primary)
- Last action
- Jan 15, 2026
Bottom line
This bill aims to remove financial barriers to advanced breast cancer screenings for high-risk individuals across all major health coverage types, potentially leading to earlier detection and improved health outcomes.
What it actually does
The "Find It Early Act" mandates that various health insurance plans and federal health programs, including private insurance, Medicare, Medicaid, TRICARE, and VA health care, must provide coverage for additional breast cancer screenings with no cost-sharing. This expanded coverage applies to individuals at increased risk of breast cancer or with dense breast tissue, and for others determined by a healthcare provider to need such screenings based on factors like age, race, ethnicity, or family history, following guidelines from the National Comprehensive Cancer Network and American College of Radiology.
Proponents argue
Proponents argue that early detection of breast cancer is crucial for successful treatment and improved patient outcomes, especially for high-risk individuals or those with dense breast tissue where standard mammograms may be less effective. Eliminating cost-sharing will ensure that financial burdens do not prevent these necessary screenings, thereby reducing disparities in access to care and ultimately saving lives. They emphasize that the bill aligns with current medical guidelines from leading professional organizations.
Opponents contend
Potential opponents might raise concerns about the increased costs to health plans, insurers, and federal programs, which could translate to higher premiums or taxpayer burdens. They might argue that while early detection is valuable, mandating specific screening technologies and frequencies without considering broader cost-effectiveness could lead to over-screening or unnecessary procedures, potentially straining healthcare resources.
The bill is moderately complex due to its numerous statutory amendments, but the core policy is clear, making it accessible for an informed reader to understand its implications within a reasonable timeframe.
Section 2(a)
Mandated No-Cost-Sharing Coverage for High-Risk Individuals in Private Health Plans
This section amends the Public Health Service Act (PHSA), Employee Retirement Income Security Act (ERISA), and the Internal Revenue Code (IRC) to require most group and individual health insurance plans to cover additional breast cancer screenings without cost-sharing. This applies to individuals at increased risk of breast cancer or with dense breast tissue, and others deemed necessary by a healthcare provider, following National Comprehensive Cancer Network (NCCN) and American College of Radiology (ACR) guidelines, effective January 1, 2026. It also extends this requirement to "grandfathered" health plans.
Supporters argue
Supporters argue this ensures equitable access to critical early detection tools, especially for those at higher risk, preventing financial barriers from delaying or denying care.
Critics contend
Critics might argue this mandate could increase premiums for all insured individuals, as the costs of these additional screenings are absorbed by the plans.
Tradeoffs
Balances the benefit of early detection for high-risk individuals against potential increases in overall healthcare costs and insurance premiums.
Section 2(b)
Expanded Breast Screening Coverage for Medicare Beneficiaries
This section amends the Social Security Act to expand Medicare coverage for breast cancer screenings. It mandates coverage, with no cost-sharing, for advanced screenings (like ultrasounds, MRIs, etc.) for individuals at increased risk or with dense breast tissue, and others determined by a provider to need them, following NCCN/ACR guidelines, starting January 1, 2026. This also applies to Medicare Advantage plans.
Section 2(c)
Enhanced Breast Screening Coverage and No Cost-Sharing for Medicaid Recipients
This section amends the Social Security Act to include advanced breast cancer screenings as a covered medical assistance service under Medicaid, with no cost-sharing. This applies to individuals at increased risk or with dense breast tissue, and others determined by a provider to need them, following NCCN/ACR guidelines. States are given a delayed effective date if state legislation is required.
Section 2(d)
No-Cost-Sharing Breast Screenings for Service Members and Dependents under TRICARE
This section amends Title 10 of the U.S. Code to mandate coverage for advanced breast cancer screenings with no cost-sharing for service members, retirees, and their families covered by TRICARE. This applies to high-risk individuals or those with dense breast tissue, and others determined by a provider to need them, following NCCN/ACR guidelines, effective January 1, 2026.
Section 2(e)
Expanded Breast Screening Coverage and No Cost-Sharing for Veterans
This section amends Title 38 of the U.S. Code to require the Department of Veterans Affairs (VA) to furnish advanced breast cancer screenings with no cost-sharing to eligible veterans. This applies to high-risk veterans or those with dense breast tissue, and others determined by a provider to need them, following NCCN/ACR guidelines, effective January 1, 2026, regardless of their enrollment status in the VA's annual patient enrollment system.
The bill mandates coverage for screenings "as determined in accordance with the most recent applicable American College of Radiology Appropriateness Criteria or the most recent applicable guidelines of the National Comprehensive Cancer Network" and "furnished at such frequency as is recommended in guidelines set forth by the National Comprehensive Cancer Network."
Sections 2(a)(1), 2(b)(1)(C), 2(c)(1)(A)(iv), 2(d)(1)(B), 2(e)(1)(2)
Why it matters:This is standard legislative practice for medical coverage bills, allowing the covered services to evolve with medical science without requiring new legislation each time guidelines are updated. It avoids making the statute overly prescriptive on clinical details.
Case for: This approach ensures that coverage remains aligned with the latest medical evidence and best practices, adapting as screening technologies and risk assessments improve. It provides flexibility and relies on expert consensus.
Case against: It could be argued that this delegates significant policy-making authority regarding covered benefits to unelected professional bodies, potentially reducing direct congressional oversight over the scope and cost of mandated benefits.
Estimated impact: This mechanism defines the actual scope and cost of the mandated coverage, which could change over time as medical guidelines evolve.